Skip to content

Practice Based Nutrition Intervention-2

Practice Based Nutrition Intervention-2

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01700868
Acronym
PBNI-2
Enrollment
15
Registered
2012-10-04
Start date
2014-07-31
Completion date
2015-07-31
Last updated
2015-10-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus, Type 2

Keywords

Diabetes Mellitus, Type 2, Diet, Vegetarian, Diet, Fat-Restricted, Glycemic Index

Brief summary

This study aims to test hypotheses that are potentially important to diabetes management, with practical implications for reducing the medical, personal, and economic costs of the disease. Anticipated outcomes include reductions in glycosylated hemoglobin that are significantly greater than those achievable with current diet recommendations, reductions in medication use among many intervention-group participants, beneficial changes in body weight and serum lipid concentrations, and a demonstration of the acceptability of the intervention diet. Progress toward these goals could refine dietary guidance for individuals with diabetes, increase treatment expectations, and reduce the massive burden the disease currently imposes. The study further attempts to translate a dietary intervention studied in a clinical research setting to a medical practice. This will contribute to developing a model for diabetes care that can be used widely.

Detailed description

Specific Aim 1 tests the hypothesis that the nutrition intervention (low-fat, low-GI, vegan diet; henceforth called the 'vegan diet') improves glycemic control, body weight, plasma lipid concentrations, blood pressure, and indices of renal function in a within-group analysis. Glycosylated hemoglobin is the primary dependent variable, as well as fasting plasma glucose and urinary albumin and creatinine concentrations. The within-group changes in these variables from baseline to week 20, one-year follow-up will be compared. Specific Aim 2 tests the hypothesis that the vegan diet is more effective than standard nutrition care for improving glycemic control, body weight, plasma lipid concentrations, blood pressure, and indices of renal function in individuals with type 2 diabetes. Glycosylated hemoglobin is the primary dependent variable, as well as fasting plasma glucose and urinary albumin and creatinine concentrations in both the intervention and control groups. The between-groups differences in the changes in these variables from baseline to week 20, and one-year follow-up will be compared. Specific Aim 3 tests the hypothesis that the vegan diet is sustainable among individuals with type 2 diabetes for a 20-week period, with weekly classes, and in a follow-up period of one year with limited professional support. This will be assessed by 3-day dietary records at weeks 0, 20 and one-year follow-up. Specific Aim 4 tests the hypothesis that the vegan diet has an acceptability that is comparable to that of standard nutrition care among individuals with type 2 diabetes. This hypothesis will be addressed by quantitatively assessing adherence to and acceptability of the intervention and control diets, using the 3-day dietary record, the Food Acceptability Questionnaire, and the Eating Inventory, as described below. Specific Aim 5 tests the hypothesis that the effects of the dietary interventions on A1c and body weight are reduced in individuals with the A1 and B1 alleles of the DRD2 gene. This will be assessed through Taq1 A1 and B1 genotype determination at baseline.

Interventions

OTHERVegan diet

A diet devoid of any animal products. Low-fat, low-Glycemic Index, vegan diet.

OTHERAmerican Diabetes Association guidelines

Participants will follow individualized diet plans following ADA guidelines

Sponsors

Physicians Committee for Responsible Medicine
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
SINGLE (Caregiver)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. a diagnosis of type 2 diabetes mellitus, as defined by a fasting plasma glucose concentration ≥126 mg/dl on 2 occasions or a prior physician's diagnosis of type 2 diabetes with the use of hypoglycemic medications for at least 6 months 2. male or female 3. A1c between 6.5% and 10.5% 4. age at least 18 years 5. ability and willingness to participate in all components of the study 6. willingness to be assigned to either a low-fat, vegan diet or to standard care 7. diabetes medications unchanged for 1 month prior to volunteering for the study 8. patient of Dr. Mark Sklar

Exclusion criteria

1. body mass index \>45 kg/m2 2. alcohol consumption of more than 2 drinks per day or the equivalent, episodic increased drinking (e.g., more than 2 drinks per day on weekends), or a history of alcohol abuse or dependency followed by any current use 3. use of recreational drugs in the past 6 months (past drug use, if fully recovered, is not a criteria for exclusion) 4. pregnancy 5. history of severe mental illness (with current unstable status) 6. likely to be disruptive in group sessions (as determined by research staff) 7. Signs/symptoms of acute uncontrolled diabetes (including but not limited to polyuria, polydipsia, blurred vision, uncontrolled weight loss) 8. unstable medical status 9. already following a low-fat, vegetarian diet 10. an inordinate fear of blood draws 11. inability to maintain current medication regimen 12. lack of English fluency

Design outcomes

Primary

MeasureTime frame
hemoglobin A1C (diabetes management)20 weeks

Secondary

MeasureTime frame
24-Hour Multi-Pass Dietary Recalls20 Weeks
3-day dietary records20 Weeks
International Physical Activity Questionnaire20 Weeks
Food Acceptability Questionnaire20 Weeks
Eating Inventory20 Weeks
CESD-R (Center for Epidemiologic Studies Depression Scale: Review and revision)20 Weeks
Beck Depression Inventory II (BDI-II)20 Weeks
Body Weight20 Weeks
Height20 Weeks
Glucose20 Weeks
Comprehensive Metabolic Panel20 Weeks & one-year follow up
Serum cholesterol and triacylglycerol concentrations20 Weeks
Urinary albumin and creatinine20 Weeks
Genotyping for Taq1 A and Taq1 B polymorphisms, and APOE (Apolipoprotein E)20 Weeks
Waist and hip circumference20 Weeks
Dietary Acceptability20 Weeks
Blood Pressure20 Weeks

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026